Blockchain Registration Transaction Record

LIXTE Biotechnology Advances Ovarian Cancer Trial and Proton Therapy

LIXTE Biotechnology Holdings advances lead candidate LB-100 in ovarian cancer trial and grows Liora Technologies subsidiary for proton therapy. Read the latest updates.

LIXTE Biotechnology Advances Ovarian Cancer Trial and Proton Therapy

This news matters because LIXTE's progress with LB-100 could lead to new treatment options for ovarian cancer and other solid tumors, potentially improving patient outcomes. Additionally, the development of the LiGHT System for proton therapy may offer more precise and effective cancer treatment, broadening the company's impact on oncology. Investors and patients alike should watch these developments as they could reshape cancer care.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x27d4925d7f2929b989fe9e6a952bf760be620232c2c0d575fa7b4af3693e7e1f
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintvoltvXqJ-e7479a37bb839cbda27e3ba8558e0f7b